PetVivo to Exhibit Spryng with OsteoCushion™ Technology at the American Association of Equine Practitioners Convention on December 8-10, 2024
PetVivo Holdings (OTCQB: PETV) announced its participation in the American Association of Equine Practitioners (AAEP) convention from December 8-10, 2024, in Orlando, Florida. The company will showcase Spryng™ with OsteoCushion™ Technology, their lead product for joint pain management. Spryng is an intra-articular injectable veterinary device using sterilized, extra-cellular matrix microparticles that integrate with the animal's subsynovial tissue to restore proper joint mechanics. The product aids in managing noninfectious joint pain, including joint instability, degenerative joint disease, and osteoarthritis.
PetVivo Holdings (OTCQB: PETV) ha annunciato la sua partecipazione alla conferenza dell'American Association of Equine Practitioners (AAEP) che si terrà dal 8 al 10 dicembre 2024, a Orlando, Florida. L’azienda presenterà Spryng™ con OsteoCushion™ Technology, il loro prodotto di punta per la gestione del dolore articolare. Spryng è un dispositivo veterinario iniettabile intra-articolare che utilizza microparticelle di matrice extracellulare sterilizzate che si integrano con il tessuto subsinoviale dell'animale per ripristinare la corretta meccanica articolare. Il prodotto aiuta nella gestione del dolore articolare non infettivo, inclusi instabilità articolari, malattia articolare degenerativa e osteoartrite.
PetVivo Holdings (OTCQB: PETV) anunció su participación en la convención de la American Association of Equine Practitioners (AAEP) que se llevará a cabo del 8 al 10 de diciembre de 2024, en Orlando, Florida. La empresa mostrará Spryng™ con OsteoCushion™ Technology, su producto principal para la gestión del dolor articular. Spryng es un dispositivo veterinario injectable intraarticular que utiliza micropartículas de matriz extracelular esterilizadas que se integran con el tejido subsinovial del animal para restaurar la mecánica articular adecuada. El producto ayuda en la gestión del dolor articular no infeccioso, incluyendo inestabilidad articular, enfermedad articular degenerativa y osteoartritis.
페트비보 홀딩스 (OTCQB: PETV)는 2024년 12월 8일부터 10일까지 플로리다주 올랜도에서 열리는 미국 마마의사 협회(AAEP) 회의에 참여한다고 발표했습니다. 이 회사는 관절 통증 관리용 주요 제품인 Spryng™과 OsteoCushion™ 기술을 선보일 예정입니다. Spryng는 멸균된 세포외 기질 미세입자를 사용하는 관절 내 주입형 수의학 기기로, 동물의 피하 관절 조직과 통합되어 적절한 관절 기구를 복원합니다. 이 제품은 비감염성 관절 통증, 관절 불안정성, 퇴행성 관절 질환 및 골관절염 관리에 도움을 줍니다.
PetVivo Holdings (OTCQB: PETV) a annoncé sa participation à la convention de l'American Association of Equine Practitioners (AAEP) qui se tiendra du 8 au 10 décembre 2024, à Orlando, en Floride. L'entreprise présentera Spryng™ avec la technologie OsteoCushion™, son produit phare pour la gestion de la douleur articulaire. Spryng est un dispositif vétérinaire injectable intra-articulaire utilisant des microparticules de matrice extracellulaire stérilisées qui s'intègrent au tissu subsynovial de l'animal pour restaurer la mécanique articulaire appropriée. Le produit aide à gérer la douleur articulaire non infectieuse, y compris l'instabilité articulaire, les maladies articulaires dégénératives et l'arthrose.
PetVivo Holdings (OTCQB: PETV) gab die Teilnahme an der Konferenz der American Association of Equine Practitioners (AAEP) bekannt, die vom 8. bis 10. Dezember 2024 in Orlando, Florida, stattfinden wird. Das Unternehmen wird Spryng™ mit OsteoCushion™ Technologie, sein Hauptprodukt zur Behandlung von Gelenkschmerzen, präsentieren. Spryng ist ein intraartikuläres injizierbares veterinärmedizinisches Gerät, das sterilisierten, extrazellulären Matrixmikropartikeln verwendet, die mit dem subsynovialen Gewebe des Tieres integriert werden, um die richtige Gelenkmechanik wiederherzustellen. Das Produkt hilft bei der Behandlung von nicht-infektiösen Gelenkschmerzen, einschließlich Gelenkinstabilität, degenerativen Gelenkerkrankungen und Arthrose.
- None.
- None.
MINNEAPOLIS, MN, Nov. 26, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of medical devices and biomedical therapeutics for equines and companion animals, will exhibit at the American Association of Equine Practitioners (“AAEP”) convention to be held December 8th to December 10th, 2024 at the Orange County Convention Center, Exhibit Halls B, C and D, in Orlando, Florida.
PetVivo will exhibit its lead product, Spryng ™ with OsteoCushion™ Technology. Spryng is an intra-articular injectable veterinary medical device composed of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
“We are incredibly excited to participate again this year at the AAEP Convention. The AAEP provides us an excellent opportunity to demonstrate to leading equine veterinarians our innovative medical device for the management of osteoarthritis, Spryng with OsteoCushion Technology,” said PetVivo CEO, John Lai. “We welcome the opportunity to support AAEP and participate in this convention to explain the advantages of Spryng including the beneficial results we have witnessed when administered to horses and companion animals throughout the U.S.”
Visitors to the AAEP Convention can see the Spryng exhibit at booth #929 on December 8, 2024, 10:00 a.m. to 6:00 p.m., December 9, 2024, 10:00 a.m. to 6:00 p.m. and December 10, 10:00 a.m. to 4:00 p.m.
For more information about Spryng, please contact info1@petvivo.com or visit petvivo.com and sprynghealth.com.
About PetVivo Holdings
PetVivo Holdings, Inc. (OTCQB: PETV, PETVW) is a biomedical device company focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The company is pursuing a strategy of developing and commercializing human therapies for the treatment of companion animals in capital and time efficient ways. A key component of this strategy is an accelerated timeline to revenues for veterinary medical devices that can enter the market much earlier than more stringently regulated human pharmaceuticals and biologics.
PetVivo has developed a robust pipeline of products for the medical treatment of animals and people, with a portfolio of 21 patents that protect the company's biomaterials, products, production processes and methods of use. The company’s commercially launched flagship product, Spryng™ with OsteoCushion™ Technology, is a veterinarian-administered, intra-articular injectable designed for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses.
For more information about PetVivo and its revolutionary Spryng with OsteoCushion Technology, email info1@petvivo.com or visit petvivo.com or sprynghealth.com.
Disclosure Information
PetVivo uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the company’s Investor Relations website, in addition to following the company’s press releases, SEC filings, public conference calls, presentations and webcasts.
Forward-Looking commercial Statements
The foregoing information regarding PetVivo Holdings, Inc. (the “Company”) may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216
FAQ
When will PetVivo (PETV) exhibit at the AAEP Convention 2024?
What is PetVivo's (PETV) Spryng with OsteoCushion Technology used for?
Where can visitors find PetVivo's (PETV) booth at the 2024 AAEP Convention?
